Neoplastic Process
FDA Requests Additional Study on AstraZeneca’s Imfinzi for Lung Cancer Treatment
FDA, AstraZeneca, Imfinzi, Lung Cancer, Surgery, Adcomm
Geron Corporation Loses Chief Commercial Officer Following FDA Approval of RYTELO
Geron Corporation, Chief Commercial Officer, FDA Approval, RYTELO, Blood Cancer Treatment
RAPT Therapeutics Announces Significant Workforce Reduction Following Clinical Hold on Zelnecirnon Trials
RAPT Therapeutics, zelnecirnon, clinical hold, workforce reduction, FDA, clinical trials, atopic dermatitis, asthma, oncology, CCR4 agonist
AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study
AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer
Agenus Faces Uphill Battle After FDA Rejects Accelerated Approval for Cancer Drug Combo
Agenus, FDA, Cancer Drug Combo, BOT/BAL, Colorectal Cancer, Accelerated Approval, Stock Selloff
FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search
Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership
Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications
NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation
Ipsen Licenses Novel Antibody-Drug Conjugate from Foreseen Biotechnology for Cancer Treatment
Ipsen, Foreseen Biotechnology, Antibody-Drug Conjugate (ADC), Cancer Treatment, Global Licensing Agreement, FS001
Myricx Bio Secures £90m ($114m) Series A Financing to Advance Novel NMTi ADC Therapeutics
Myricx Bio, Series A Financing, NMTi ADC Therapeutics, Novo Holdings, Lilly, Cancer Treatment
Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq